Pivotal role of renal kallikrein-kinin system in the development of hypertension and approaches to new drugs based on this relationship

Japanese Journal of Pharmacology

Volumn 70, Issue 2, 1996, Pages 95-128

  Katori, Makoto ^a   Majima, Masataka ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Hypertension; Kininogen; Renal kallikrein; Sodium accumulation; Urinary kinin

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANTIHYPERTENSIVE AGENT; BRADYKININ; DEOXYCORTICOSTERONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENKEPHALINASE INHIBITOR; KALLIKREIN; KININ; KININASE; KININOGEN;

ALDOSTERONE RELEASE; ANIMAL MODEL; BLOOD VESSEL REACTIVITY; CEREBROSPINAL FLUID; CONGENITAL DISORDER; ERYTHROCYTE; ESSENTIAL HYPERTENSION; GENETICS; HEREDITARY HYPERTENSION; HORMONE SENSITIVITY; HUMAN; HYPERTENSION; KALLIKREIN KININ SYSTEM; KALLIKREIN URINE LEVEL; KIDNEY; NEPHRON; NONHUMAN; POTASSIUM INTAKE; RAT; REVIEW; SALT LOADING; SODIUM RETENTION; SODIUM URINE LEVEL; VASCULAR SMOOTH MUSCLE;

EID: 0029970584     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.70.95     Document Type: Review

References (247)

1. Williams RR and Hunt SC: Genetic basis of familial dyslipidemia and hypertension: 15-year results from Utah. Am J Hypertens 6, 319S-327S (1993)
2. Naftilan AJ, Williams RR, Burt D, Paul M, Pratt RE, Hobart P, Chirgwin J and Dzau VJ: A lack of genetic linkage of renin gene restriction fragment length polymorphisms with human hypertension. Hypertension 4, 614-618 (1989)
3. Jeunemaitre X, Lifton RP, Hunt SC, Williams RR and Lalouel J-M: Absence of linkage between the angiotensin converting enzyme locus and human essential hypertension. Nat Genet 1, 72-75 (1992)
4. + antiporter as a candidate gene in human essential hypertension. Hypertension 17, 8-14 (1991)
5. Jeunemaitre X, Soubrier F, Kotelevtsev YV, Lifton RP, Williams CS, Charru A, Hunt SC, Hopkins PN, Williams RR, Lalouel J-M and Corvol P: Molecular basis of human hypertension: Role of angiotensinogen. Cell 71, 169-180 (1992)
6. Corvol P: Role of the renin-angiotensin-aldosterone system in blood pressure regulation and in human hypertension: new sights from molecular genetics. Recent Prog Horm Res 50, 287-308 (1995)
7. Tanimoto K, Sugiyama F, Goto Y, Ishida J, Takimoto E, Yagami K, Fukamizu A and Murakami K: Angiotensinogen-deficient mice with hypotension. J Biol Chem 269, 31334-31337 (1994)
8. Sugaya T, Nishimatsu S, Tanimoto K, Takimoto E, Yamagishi T, Imamura K, Goto S, Imaizumi K, Hisada Y, Otsuka A, Uchida H, Sugiura M, Fukuda K, Fukamizu A and Murakami K: Angiotensin II type la receptor-deficient mice with hypotension and hyperreninemia. J Biol Chem 270, 18719-18722 (1995)
9. Hasstedt SJ, Wu LL, Ash KO, Kuida H and Williams RR: Hypertension and sodium-lithium countertransport in Utah pedigrees: evidence for major locus inheritance. Am J Hum Genet 43, 14-22 (1988)
10. Hasstedt ST, Hunt SC, Wu LL and Williams RR: The inheritance of intraerythrocytic sodium level. Am J Med Genet 29, 193-203 (1988)
11. Berry TD, Hasstedt SJ, Hunt SC, Wu LL, Smith JB, Ash KO, Kuida H and Williams RR: A gene for high urinary kallikrein may protect against hypertension in Utah kindreds. Hypertension 3, 3-8 (1989)
12. Hunt SC, Hasstedt SJ, Wu LL and Williams RR: A gene-environmental interaction between inferred kallikrein genotype and potassium. Hypertension 22, 161-168 (1993)
13. Scicli AG and Carretero OA: Renal kallikrein-kinin system. Kidney Int 29, 120-130 (1986)
14. Carretero OA and Scicli AG: The renal kallikrein-kinin system. Am J Physiol 238, F247-F255 (1980)
15. Mayfield RK and Margolius HS: Renal kallikrein-kinin system. Relation to renal function and blood pressure. Am J Nephrol 3, 145-155 (1983)
16. Carretero OA and Scicli AG: Kinins as regulators of blood flow and blood pressure. In Hypertension: Pathophysiology, Diagnosis, and Management, Edited by Laragh JH and Brenner BM, Chapter 52, pp 805-817, Raven Press, Ltd, New York (1990)
17. Bhoola KD, Figueroa CD and Worthy K: Bioregulation of kinins: Kallikreins, kininogens, and kininases. Pharmacol Rev 44, 1-80 (1992)
18. Margolius HS: Kallikreins and kinins. Some unanswered questions about system characteristics and roles in human disease. Hypertension 26, 221-229 (1995)
19. Shölkens BA: Kinins in the cardiovascular system. Immunopharmacology, Supp (in press)
20. Wang J, Xiong W, Yang S, Davis T, Chao J and Chao J: Human tissue kallikrein induces hypotension in transgenic mice. Hypertension 23, 236-243 (1994)
21. 2 bradykinin receptor gene in mice eliminates bradykinin action in smooth muscle and neurons. J Biol Chem 270, 13706-13710 (1995)
22. Majima M and Katori M: Approaches to the development of novel antihypertensive drugs: crucial role of the renal kallikrein-kinin system. Trends Pharmacol Sci 16, 239-246 (1995)
23. Nossel HL: The contact system. In Human Blood Coagulation, Haemostasis and Thrombosis, Edited by Biggs R, pp 79-132, Blackwell Sci Pub, London (1972)
24. Pierce JV and Webster ME: Human plasma kallikreins: isolation and chemical studies. Biochem Biophys Res Commun 5, 353-357 (1961)
25. Kato H, Enjyoji K, Miyata T, Hayashi I, Oh-ishi S and Iwanaga S: Demonstration of arginyl-baradykinin moiety in rat HMW kininogen: Direct evidence for liberation of bradykinin by rat glandular kallikreins. Biochem Biophys Res Commun 127, 289-295 (1985)
26. Inoue H, Fuki K and Miyake Y: Identification and structure of the rat true tissue kallikrein gene expressed in the kidney. J Biochem 105, 834-840 (1989)
27. Berg T, Bradshaw RA, Carretero OA, Chao J, Chao L, Clements JA, Fahnestock M, Fritz H, Gauthier F, MacDonald RJ, Margolius HS, Morris BJ, Richards RJ and Scicli AG: A common nomenclature for members of the tissue (glandular) kallikrein gene families. Agents Actions Supp 38/1, 19-25 (1992)
28. Clements J, Mukhtar A, Ehrlich A and Fuller P: A reevaluation of the tissue-specific pattern of expression of the rat kallikrein gene family. Agents Actions Supp 38/I, 34-41 (1992)
29. Riegman PH, Vlietstra RJ, Suurmeijer L, Cleutjens CB and Trapman J: Characterization of the human kallikrein locus. Genomics 14, 6-11 (1992)
30. Uchida Y, Tanaka K, Harada Y, Ueno A and Katori M: Activation of plasma kallikrein-kinin system and its significant role in pleural fluid accumulation of rat carrageenin-induced pleurisy. Inflammation 7, 121-131 (1983)
31. Majima M, Tani Y and Katori M: Loss of the activity of human coagulation factor XII by a chymotrypsin-like protease activated in rat mast cells during degradation with compound 48/80. Thromb Res 46, 855-867 (1987)
32. Katori M, Majima M, Odoi-Adome R, Sunahara N and Uchida Y: Evidence for involvement of a plasma kallikrein-kinin system in the immediate hypotension produced by endotoxin in anaesthetized rats. Br J Pharmacol 98, 1381-1391 (1989)
33. Matsumoto K, Yamamoto T, Kamata R and Maeda H: Pathogenesis of serratial infection: Activation of Hageman factor-prekallikrein cascade by serratial protease. J Biochem 976, 739-749 (1984)
34. Molla A, Yamamoto T, Akaike T, Miyoshi S and Maeda H: Activation of Hageman factor and prekallikrein and generation of kinin by various microbial proteinases. J Biol Chem 264, 10589-10594 (1989)
35. Kaminishi H, Tanaka M, Cho T, Maeda H and Hagihara Y: Activation of the plasma kallikrein-kinin system by Candida albicans proteinase. Infect Immun 58, 2139-2143 (1990)
36. Maruo K, Akaike T, Matsumura Y, Kohmoto S, Inada Y, Ono T, Arao T and Maeda H: Triggering of the vascular permeability reaction by activation of the Hageman factor-prekallikrein system by house dust mite proteinase. Biochim Biophys Acta 1074, 62-68 (1986)
37. 2 and that of leukocyte migration by LTB4 in inlfammatory models. Dermatologica 179, Supp 60-63 (1989)
38. Majima M, Sunahara N, Harada Y and Katori M: Detection of the degradation products of bradykinin by enzyme immunoassays as markers for the release of kinin in vivo. Biochem Pharmacol 45, 559-567 (1993)
39. Nustad K, Orstravik TB and Gautivik KM: Radioimmunological measurement of rat submandibular gland kallikrein in tissue and serum (abstract). Microvasc Res 15, 115-116 (1978)
40. Rabito SF, Amin V, Scicli AG and Carretero OA: Glandular kallikrein in plasma and urine. In Adv Exp Med Biol, Vol 120A, Kinins II, Edited by Fujii S, Moriya H and Suzuki T, pp 127-142, Plenum Press, New York (1979)
41. Geiger R, Clausnitzer B, Fink E and Fritz H: Isolation of an enzymatically active glandular kallikrein from human plasma. Hoppe Seylers Z Physiol Chem 1361, 1795-1803 (1980)
42. Lawton WT, Proud D, French ME, Pierce JV, Keiser HR and Pisano JJ: Characterization and origin of immunoreactive glandular kallikrein in rat plasma. Biochem Pharmacol 30, 1731-1737 (1981)
43. Scicli AG, Mindroiu T Scicli G and Carretero OA: Blood kinins, their concentration in normal subjects and in patients with congenital deficiency in plasma prekallikrein and kininogen. J Lab Clin Med 100, 81-93 (1982)
44. Scicli AG, Orstavik TB, Rabito S, Murray RD and Carretero OA: Blood kinins after sympathetic nerve stimulation of the rat submandibular gland. Hypertension 5, 1101-1106 (1983)
45. 2 receptor antagonism on the hypotensive effects of ACE inhibtion. Br J Pharmacol 113, 717-722 (1994)
46. Pelacani A, Brunner HR and Nussberger J: Plasma kinins increase after angiotensin-converting enzyme inhibition in human subjects. Clin Sci 87, 567-574 (1994)
47. Majima M, Katori M, Ogino M, Saito M, Sugimoto K, Adachi K, Sunahara N, Katoh K, Tatemichi N and Takei Y: Failure of endogenous blood kinin levels elevated by captopril to induce hypotension in normotensive and hypertensive rats - An assay for kinin by a new ELISA. Biomed Res 17, 698-708 (1995)
48. Linz W, Wiemer G and Schoelkens BA: Contribution of bradykinin to the cardiovascular effects of ramipril. J Cardiovas Pharmacol 22, Supp 9, S1-S8 (1993)
49. Kaizu T and Margolius HS: Studies on rat renal cortical cell kallikrein. 1. Separation and measurement. Biochim Biophys Acta 411, 305-315 (1975)
50. Tomita K, Endou H and Sakai F: Localization of kallikrein-like activity along a single nephron in rabbits. Pflugers Arch 389, 91-95 (1981)
51. Omata K, Carretero OA, Scicli AG and Jackson BA: Localization of active and inactive kallikrein in the isolated tubular segments of the rabbit nephron. Kidney Int 22, 602-607 (1982)
52. Proud D, Knepper MA and Pisano JJ: Distribution of immunoreactive kallikrein along the rat nephron. Am J Physiol 244, F510-515 (1983)
53. Ostravik TB, Nustad K, Brandtzaeg P and Pierce J: Cellular origin of urinary kallikreins. J Histochem Cytochem 24, 1037-1039 (1976)
54. Ostravik TB and Inagami T: The localization of kallikrein in the rat kidney and its anatomical relationship to renin. J Histochem Cytochem 30, 385-390 (1982)
55. Figueroa CD, Caorsi I, Subiabre J and Vio CP: Immunoreactive kallikrein localization in the rat kidney: An immuno-electron-microscopic study. J Histochem Cytochem 32, 117-121 (1984)
56. Figueroa CD, Aorst I and Vio CP: Visualization of renal kallikrein in luminal and basolateral membranes: Effect of tissue processing method. J Histochem Cytochem 32, 1238-1240 (1984)
57. Vio CP and Figueroa CD: Subcellular localization of renal kallikrein by ultrastructural immunocytochemistry. Kidney Int 28, 35-42 (1985)
58. Xiong W, Chao L and Chao J: Renal kallikrein mRNA localization by in situ hybridization. Kidney Int 35, 1324-1329 (1989)
59. El-Dahr SS and Chao J: Spatial and temporal expression of kallikrein and its mRNA during nephron maturation. Am J Physiol 262, F705-F711 (1992)
60. Cumming AD, Walsh T, Wojtacha D, Fleming S, Thomson D and Jenkins DAS: Expression of tissue kallikrein in human kidney. Clin Sci 87, 5-11 (1994)
61. Bevan DR, MacFarlane NAA and Mills IH: The dependence of urinary kallikrein excretion on renal artery pressure. J Physiol (Lond) 241, 34P-35P (1974)
62. Keiser HR, Andrews MJ Jr, Guyton RA, Margolius HS and Pisano JJ: Urinary kallikrein in dogs with constriction of one renal artery. Proc Soc Exp Biol Med 151, 53-56 (1976)
63. Bonner G, Schwertschlag U, Martin-Grez M and Gross F: Effect of changes in perfusion pressure on urinary kallikrein in the isolated perfused rat kidney. Renal Physiol 6, 288-294 (1983)
64. Maier M and Binder BB: Dependence of urokallikrein excretion on the perfusion pressure in explanted perfused kidneys. In Adv Exp Med Biol, Vol 120B, Kinins II, Edited by Fujii S, Moriya H and Suzuki T, pp 527-538, Plenum Press, New York (1979)
65. Misumi J, Alhenc-Gelas F, Marre M, Marchetti J, Corvol P and Menard J: Regulation of kallikrein and renin release by the isolated perfused rat kidney. Kidney Int 24, 58-65 (1983)
66. Margolius HS, Horowits D, Geller RG, Alexander RW, Gill JR Jr, Pisano JJ and Keiser HR: Urinary kallikrein excretion in normal man. Relationships of sodium intake and sodium-retaining steroids. Circ Res 35, 812-819 (1974)
67. Margolius HS, Horowitz D, Pisano JJ and Keiser HR: Urinary kallikrein excretion in hypertensive man. Relationships to sodium intake and sodium-retaining steroids. Circ Res 35, 820-825 (1974)
68. Geller RG, Margolius HS, Pisano JJ and Keiser HR: Effects of mineralocorticoids, altered sodium uptake and adrenalectomy on urinary kallikrein in rats. Circ Res 31, 857-861 (1972)
69. Bascands JL, Girolami J-P, Pecher C, Moatti J-P, Manuel Y and Suc JM: Compared effects of a low and a high sodium diet on the renal and urinary concentration and activity of kallikrien in noraml rats. J Hypertens 5, 311-315 (1987)
70. Omata K, Carretero OA, Itoh S and Scicli AG: Active and inactive kallikrein in rabbit connecting tubules and urine during low and normal sodium intake. Kidney Int 24, 714-718 (1983)
71. Margolius HS, Geller R, Pisano J and Sjoerdsma A: Altered urinary kallikrein excretion in human hypertension. Lancet ii, 1063-1065 (1971)
72. Halushka PV, Wohltmann H, Privitera PJ, Hurwitz G and Margolius HS: Bartter's syndrome. Urinary prostaglandin E-like material and kallikrein; indomethacin effects. Ann Intern Med 87, 281-286 (1977)
73. Miyashita A: Urinary kallikrein determination and its physiological role in human kidney. Jpn J Urol 62, 507-518 (1971)
74. Katori M, Majima M, Mohsin SSJ, Hanazuka M and Mizokami S: Essential role of kallikrein-kinin system in suppression of blood pressure rise during the developmental stage of hypertension induced by deoxycorticosteroid acetate-salt in rats. Agents Actions Supp 38/III, 235-242 (1992)
75. Nishimura K, Alhenc-Gelas F, White A and Erdos EG: Activation of membrane bound kallikrein and renin in the kidney. Proc Natl Acad Sci USA 77, 4975-4978 (1980)
76. Marchetti J, Imbert-Teboul M, Alhec-Gelas F, Allegrini J, Menard J and Morel F : Kallikrein along the rabbit micro-dissected nephron: A micromethod for its measurement. Effect of adrenalectomy and DOCA treatment. Pflugers Arch 401, 27-33 (1984)
77. Martin-Grez M, Bonner G and Gross F: The influence of isotonic saline administration of the urinary excretion of kallikrein in rats. Biochem Pharmacol 33, 3585-3590 (1984)
78. Lieberthal W, Oza NB, Bernard DB and Levinsky NG: Effects of alterations in sodium and water metabolism on urinary excretion of active and inactive kallikrein in man. J Clin Endocrinol Metab 56, 513-519 (1983)
79. Horowitz D, Margolius HS and Keiser HR: Effects of dietary potassium and race on urinary excretion of kallikrein and aldosterone in man. J Clin Endocrinol Metab 47, 296-299 (1978)
80. Vio CP and Figueroa CD: Evidence for a stimulatory effect of high potassium diet on renal kallikrein. Kidney Int 31, 1327-1334 (1987)
81. Himathongkam T, Dulhy RG and Williams GH: Potassium-aldosterone-renin interrelationships. J Clin Endocrinol Metab 41, 153-159 (1975)
82. Quinn SJ, Cornwall MC and Williams GH: Electric properties of isolated rat adrenal glomerulosa and fasciculata cells. Endocrinology 120, 903-914 (1987)
83. Fejes-Toth G, Zahajszky T and Filep J: Effect of vasopressin on renal kallikrein excretion. Am J Physiol 239, F388-F392 (1980)
84. Adachi K, Majima M, Katori M and Nishijima M: Oxytocin-induced natriuresis mediated by the renal kallikrein-kinin system in anesthetized male rats. Jpn J Pharmacol 67, 243-252 (1995)
85. Geiger R and Mann K: A kallikrien-specific inhibitor in rat kidney tubules. Hoppe Seyler Z Physiol Chem 375, 553-558 (1976)
86. Chao J, Chai KX, Chen L-M, Xiong W, Chao S, Woodley-Miller C, Wang L, Lu HS and Chao L: Tissue kallikrein-binding protein is a serpin. I. Purification, characterization, and distribution in normotensive and spontaneously hypertensive rats. J Biol Chem 266, 16392-16401 (1990)
87. Chai KX, Ma J-X, Murray SR, Chao J and Chao L: Molecular cloning and analysis of the rat kallikrein-binding protein gene. J Biol Chem 266, 16029-16036 (1991)
88. Zhou GX, Chao L and Chao J: Kallistatin: A novel human tissue kallikrein inhibitor. J Biol Chem 267, 25873-25880 (1992)
89. Yang T, Terada Y, Nonoguchi H, Tsujino M, Tomita K and Marumo F: Distribution of kallikrein-binding protein mRNA in kidneys and difference between SHR and WKY rats. Am J Physiol 267, F325-F330 (1994)
90. Hial V, Keiser HR and Pisano JTJ: Origin and content of methionyl-lysyl-bradykinin, lysyl-bradykinin and bradykinin in human urine. Biochem Pharmacol 25, 2499-2503 (1976)
91. Pisano JJ, Yates K and Pierce JV: Kininogen in human urine. Agents Actions 8, 1-2 (1978)
92. Proud D, Perkins M, Pierce JV, Yates K, Highet P, Herrig P, Mark MM, Bahu R, Carone F and Pisano JJ: Characterization and localization of human renal kininogen. J Biol Chem 256, 10634-10639 (1981)
93. Figueroa CD, MacIver AG, Mackenzie JC and Bhoola KD: Localization of immunoreactive kininogen and tissue kallikrein in the human nephron. Histochemistry 89, 437-442 (1988)
94. Chao J, Swain C, Chao S, Xiong W and Chao L: Tissue distribution and kininogen gene expression after acute-phase inflammation. Biochim Biophys Acta 964, 329-339 (1988)
95. Iwai N, Matsunaga M, Kita T, Tei M and Kawai Ch: Detection of low molecular kininogen messenger RNA in human kidney. J Hypertens 6, Supp 4, S399-S400 (1988)
96. Hagiwara Y, Kojima M, Hayashi I and Oh-ishi S: Demonstration of derivation of rat urinary bradykinin from plasma low-molecular-weight kininogen: a study using kininogen-deficient rats. Biochem Biophys Res Commun 204, 1219-1224 (1994)
97. Miura T, Hayashi I, Hoshino T and Oh-ishi S: Demonstration of high-molecular-weight kininogen in kininogen-deficient rat kidneys. J Biochem 116, 59-63 (1994)
98. Carone FA, Pullman TN, Oparil S and Nakamura S: Micropuncture evidence of rapid hydrolysis of bradykinin by rat proximal tubules. Am J Physiol 230, 1420-1424 (1976)
99. Sudo J: Distribution of peptidases in the metabolization of peptide hormones, particularly angiotensin II, along the isolated single nephron of rat. Folia Pharmacol Jpn 78, 27-44 (1981) (Abstr in English)
100. Marchetti J, Roseau S and Alhenc-Gelas F: Angiotensin I converting enzyme and kinin-hydrolyzing enzymes along the rabbit single nephron. Kidney Int 31, 744-751 (1987)
101. Ikemoto F, Song GB, Tominaga M, Kanayama Y and Yamamoto K: Angiotensin-converting enzyme in the rat kidney. Activity, distribution, and response to angiotensin-converting enzyme inhibitors. Nephron 55, Supp 1, 3-9 (1990)
102. Schulz WW, Hagler HK, Buja LM and Erdos EG: Ultrastructural localozation of angiotensin I-converting enzyme (EC 3.4.15.1) and neutral metalloendopeptidase (EC 3.4.24.11) in the proximal tubules of the human kidney. Lab Invest 59, 789-797 (1988)
103. Skidgel RA, Davis RM and Erdos EG: Purification of a human urinary carboxipeptidase (kininase) distinct from carboxypeptidase A, B or N. Anal Biochem 140, 520-531 (1984)
104. Sakakibara T, Ura N, Shimamoto K, Mori Y, Saito S, Ise T, Sasa Y, Yamauchi K and Iimura O: Localization of neutral endopeptidase in the kidney determined by the stop-flow method. Adv Exp Med Biol 247B, 437-440 (1989)
105. Ura N, Carretero OA and Erdos EG: Role of renal endopeptidase 24.11 in kinin metabolism in vitro and in vivo. Kidney Int 32, 507-513 (1987)
106. Ura N, Shimamoto K, Satoh S, Kuroda S, Nomura N, Ohtomo Y, Masuda A and Iimura O: Renal kininase I, kininase II and neutral endopeptidase 24.11 activities in patients with essential hypertension, primary aldosteronism and Cushing's syndrome. Hypertens Res 16, 253-258 (1993)
107. Marinkovi DV, Ward PE, Erdos EG and Mills IH: Carboxy-peptidase-type kininase of human kidney and urine. Proc Soc Exp Biol Med 165, 6-12 (1980)
108. Majima M, Shima C, Saito M, Kuribayashi Y, Katori M and Aoyagi T: Poststatin, a novel inhibtor of bradykinin-degrading enzymes in rat urine. Eur J Pharmacol 232, 181-190 (1993)
109. Shima C, Majima M and Katori M: A stable degradation product of bradykinin, Arg-Pro-Pro-Gly-Phe, in the degradation in human plasma. Jpn J Pharmacol 60, 111-119 (1992)
110. Kuribayashi Y, Majima M and Katori M: Major kininases in rat urine are neutral endopeptidase and carboxypeptidase Y-like exopeptidase. Biomed Res 14, 191-201 (1993)
111. Majima M, Kuribayashi Y, Ikeda Y, Adachi K, Kato H, Katori M and Aoyagi T: Diuretic and natriuretic effect of ebelactone B in anesthetized rats by inhibition of a urinary carboxypeptidase Y-like kininase. Jpn J Pharmacol 65, 79-82 (1994)
112. 3H]-bradykinin in isolated nephron segments of the rabbit. Am J Physiol 246, F732-F737 (1984)
113. 22Na in the rat nephron. J Pharmacol Exp Ther 214, 119-123 (1980)
114. Tomita K, Pisano JJ and Knepper MA: Control of sodium and potassium transport in the cortical collecting duct of the rat. J Clin Invest 76, 132-136 (1985)
115. Tomita K, Pisano JJ, Brug MB and Knepper MA: Effects of vasopressin and bradykinin on anion transport by the rat cortical collecting duct. Evidence for an electroneutral sodium chloride transport pathway. J Clin Invest 77, 136-141 (1986)
116. Regoli D and Barabe J: Pharmacology of bradykinin and related kinins. Pharmacol Rev 32, 1-46 (1980)
117. 2 receptor in rat kidney by anti-peptide and anti-ligand antibodies. J Histochem Cytochem 43, 137-148 (1995)
118. Elliot AH and Nuzum FR: The urinary excretion of a depressor substance (kallikrein of Frey and Kraut) in arterial hypertension. Endocrinology 18, 462 (1934)
119. Margolius HS, Horowitz D, Pisano JJ and Keiser HR: Urinary kallikrein excretion in hypertensive man: relationships to sodium intake and sodium-retaining steroids. Circ Res 35, 820-825 (1974)
120. Carretero OA, Oza NB and Schork A: Renal kallikrein, plasma renin, and plasma aldosterone in renal hypertension. Acta Physiol Lat Am 24, 448-452 (1974)
121. Seino J, Abe K, Otsuka Y, Saito T, Irokawa N, Yasujima M, Chiba S and Yoshinaga K: Urinary kallikrein excretion and sodium metabolism in hypertensive patients. Tohoku J Exp Med 116, 359-367 (1975)
122. Horowitz D, Margolius HS and Keiser HR: Effects of dietary potassium and race on urinary excretion of kallikrein and aldosterone in man. J Clin Endocrinol Metab 47, 296-299 (1978)
123. Lechi A, Covi G, Lechi C, Corquati A, Arosio E, Zatti M and Scuro LA: Urinary kallikrein excretion and plasma renin activity in patients with essential hypertension and primary aldosteronism. Clin Sci Mol Med 55, 51-55 (1978)
124. Abe K, Yasujima M, Irokawa N, Seino M, Chiba S, Sakurai Y, Sato M, Imai Y, Saito K, Ito T, Haruyama T, Otsuka Y and Yoshinaga K: The role of intrarenal vasoactive substances in the pathogenesis of essential hypertension. Clin Sci Mol Med 55, 363s-366s (1978)
125. Mersey JH, Williams GH, Emanuel R, Dluhy RG, Wong PY and Moore TJ: Plasma bradykinin levels and urinary kallikrein excretion in normal renin essential hypertension. J Clin Endocrinol Metab 48, 642-647 (1979)
126. Keiser HR: The kallikrein-kinin system in essential hypertension. Clin Exp Hypertens 2, 675-691 (1979)
127. Shimamoto K, Ura N, Tanaka S, Ogasawara A, Nakao T, Nakanishi Y, Chao J, Margolius HS and Iimura O: Excretion of human urinary kallikrein quantity measured by a direct radioimmunoassay of human urinary kallikrein in patients with essential hypertension and secondary hypertensive disease. Jpn Circ J 45, 1092-1097 (1981)
128. Ura N, Shimamoto K, Nakao T, Ogasawara A, Tanaka S, Mita T, Nishimiya T and Iimura O: The excretion of human urinary kallikrein quantity and activity in normal and low renin subgroups of essential hypertension. Clin Exp Hypertens 5, 329-337 (1985)
129. Favre L, Jornot L, Riodel A and Vallotton M: Urinary excretion of renal prostaglandins, kallikrein, vasopressin and aldosterone in essential hypertension. Clin Exp Hypertens 7, 1663-1679 (1985)
130. Levy SB, Lilley JJ, Frigon RP and Stone RA: Urinary kallikrein and plasma renin activity as determinants of renal blood flow. J Clin Invest 60, 129-138 (1977)
131. Carretero OA and Scicli AG: The kallikrein-kinin system in humans and in experimental hypertension. Klin Wochenschr 56, Supp I, 113-125 (1978)
132. Hilme E, Herlitz H, Gyzander E and Hansson L: Urinary kallikrein excretion is low in malignant essential hypertension. J Hypertens 10, 869-874 (1992)
133. Lawton WJ and Fitz AE: Urinary kallikrein in normal renin essential hypertension. Circulation 56, 856-859 (1977)
134. Koolen ML, Daha MR, Frolich M, Van Es LA and Van Brummelen P: Direct and indirect measurement of urinary kallikrein excretion in patients wih essential hypertension and normotensives: relation to age and plasma renin and aldosterone levels. Eur J Clin Invest 14, 171-174 (1984)
135. Zschiederich H, Fleckenstein P, Geiger R, Fink E, Sinterhauf K, Philip T, Distler A and Wolffe HP: Urinary kallikrein excretion in normotensive subjects and in patients with essential hypertension. Clin Exp Hypertens 2, 693-708 (1980)
136. Shimamoto K, Masuda A, Ando T, Ura N, Nakagawa M, Mori Y, Nakagawa H, Sakakibara T, Ogata H and Iimura O: Mechanisms of suppression of renal kallikrein activity in low renin essential hypertension and renoparenchymal hypertension. Hypertension 14, 375-378 (1989)
137. Holland B, Chud JM and Braunstein H: Urinary kallikrein excretion in essential and mineralocorticoid hypertension. J Clin Invest 65, 347-356 (1980)
138. Nakahashi Y, Shimamoto K, Ura N, Tanaka S, Nisnitani T, Ishida H, Yokoyama T, Ando T and Iimura O: Comprehensive studies on the renal kallikrein-kinin system in essential hypertension. In Adv Exp Med Biol, Vol 198B, Kinins III, Part B, Edited by Greenbaum LM and Margolius HS, pp 351-357, Plenum Press, New York (1986)
139. Mitas JA, Levy SB, Holle R, Frigon RP and Stone RA: Urinary kallikrein activity in the hypertension of renal parenchymal disease. N Engl J Med 299, 162-165 (1978)
140. Keiser HG, Geller RG, Margolius HS and Pisano JJ: Urinary kallikrein in hypertensive animal models. Fed Proc 35, 199-202 (1976)
141. Girolami JP, Praddasude F, Ader JL, Tranvan T, Eche JP and Suc SP: Bilateral urinary kallikrein excretion in the Goldblatt hypertensive rats. Eur Heart J 4, 67-72 (1983)
142. Carretero OA, Amin VM, Ocholik T, Scicli AG and Koch J: Urinary kallikrein in rats bred to suseptibility and resistance to the hypertensive effect of salt: a new radioimmunoassay for its direct determination. Circ Res 42, 727-731 (1978)
143. Boenner G, Thieven B, Ruetten H, Chrosch R and Krone W: Renal kallikrein is a determinant of salt sensitivity. J Hypertens 11, Supp 5, S210-S211 (1993)
144. Ferri C, Bellini C, Carlomagno A, Perrone A and Santucci A: Urinary kallikrein and salt sensitivity in essential hypertensive males. Kidney Int 46, 780-788 (1994)
145. Carretero OA, Polomski C, Hampton A and Scicli AG: Urinary kallikrem, plasma renin and aldosterone in New Zealand genetically hypertensive (GH) rats. Clin Exp Pharmacol Physiol 3, Supp 55-59 (1976)
146. Gilboa N, Rudofsky U and Magro, A.: Urinary and renal kallikrein in hypertensive fawn-hooded (FH/Wjd) rats. Lab Invest 50, 72-78 (1984)
147. Ader J-L, Pollock DM, Butterfield MI and Arendshorst WJ: Abnormalities in kallikein excretion in spontaneously hypertensive rats. Am J Physiol 248, F396-F403 (1985)
148. Ader J-L, Tran-Van T and Praddaude F: Reduced urinary kallikein activity in rats developing spontaneous hypertension. Am J Physiol 252, F964-F969 (1987)
149. Praddaude F, Tran-Van T and Ader JL: Renal kallikrein activity in rats developing spontaneous hypetension. Clin Sci 76, 311-315 (1989)
150. Arbeit LA and Serra SR: Decreased total and active urinary kallikrein in normotensive Dahl salt susceptible rats. Kidney Int 28, 440-446 (1985)
151. Mohsin SSJ, Majima M, Katori M and Sharma JN: Important suppressive roles of the kallikrein-kinin system during the developmental stage of hypertension in spontaneously hypertensive rats. Asia Pacific J Pharmacol 7, 73-82 (1992)
152. Dilley JR, Stier CT Jr and Ardendshorst WJ: Abnormalities in glomerular function in rats developing spontaneous hypertension. Am J Physiol 246, F12-F20 (1984)
153. Figueroa CD, Bhoola KD, MacIver AG and Mackenzie JC: An ontogenic study of renal tissue kallikrein in Okamoto spontaneously hypertensive rats: Comparisons with human hypertensive nephropathy. Nephrol Dial Transplant 7, 516-525 (1992)
154. Yasujima M, Abe K, Yanno M, Kohzuki M, Omata K, Kasai Y, Saito T, Takeuchi K, Itoh S, Kanazawa M, Hiwatari M, Saito T, Sato S and Yoshinaga K: Renal kallikrein activity in spontaneously hypertensive rats. J Hypertens 5, 687-692 (1987)
155. Fuller PJ, Clements JA, Nikolaidis I, Hiwatari M and Funder JW: Expression of the renal kallikrein gene in mineralocorticoid-treated and genetically hypertensive rats. J Hypertens 4, 427-433 (1986)
156. - cotransport in resealed ghosts from erythrocytes of the Milan hypertensive rats. Biochim Biophys Acta 1111, 111-119 (1992)
157. - cotransport and kidney function in essential hypertension. J Hypertens 11, 805-813 (1993)
158. Ferrari P, Torielli L, Cirillo M, Salardi S and Bianchi G: Sodium transport kinetics in erythrocytes and inside-out vesicles from Milan rats. J Hypertens 9, 703-711 (1991)
159. Bianchi G, Toripodi G, Casari G, Salardi S, Barber BR, Garcia R and Ferrari P: Two point mutations within the adducin genes are involved in blood pressure variation. Proc Natl Acad Sci USA 91, 3999-4003 (1994)
160. Casari G, Barlassina C, Cusi D, Zagato L, Muirhead R, Righetti M, Nembri P, Amar K, Gatti M, Macciardi F, Binelli G and Bianchi G: Association of the α-adducin locus with essential hypertension. Hypertension 25, 320-326 (1995)
161. Bianchi GP, Fox U, Di Francesco GF, Giovanetti M and Bagetti D: Blood pressure changes produced by kidney cross-transplantation between spontaneously hypertensive rats and normotensive rats. Clin Sci Mol Med 47, 435-448 (1974)
162. 1 hybrids. Jpn Heart J 19, 886-894 (1978)
163. Dahl LK, Heine M and Tassinari L: Role of genetic factors in susceptibility to experimental hypertension due to chronic excess salt ingestion. Nature 194, 480-482 (1962)
164. Iwai J, Knudsen KD, Dahl LD, Heine M and Leitl G: Genetic influence on the development of renal hypertension in parabiotic rats. J Exp Med 129, 507-522 (1969)
165. Dahl LK, Heine M and Thompson K: Genetic influence of the kidneys on blood pressure - Evidence from chronic renal homografts in rats with opposite predispositions to hypertension. Circ Res 34, 94-101 (1974)
166. Beierwalter WH, Arendshorst WJ and Klemmer PJ: Electrolyte and water balance in young spontaneously hypertensive rats. Hypertension 4, 908-915 (1982)
167. Bianchi GP, Baer G, Fox U, Duzzi L, Pagetti D and Giovanetti M: Changes in renin, water balance, and sodium balance during development of high blood pressure in genetically hypertensive rats. Circ Res 36, I-153-I-161 (1975)
168. Rapp JP, Wang S-M and Dene H: A genetic polymorphism in the renin gene of Dahl rats cosegregates with blood presssure. Science 243, 542-544 (1989)
169. Samani NJ, Brammar WJ and Swales JD: A major structural abnormality in the renin gene of the spontaneously hypertensive rat. J Hypertens 7, 249-254 (1989)
170. Kurz TW, Simonet K, Kabra PM, Wolfe S, Chan L and Hjelle BL: Cosegregation of the renin allele of the spontaneously hypertensive rat with an increase in blood pressure. J Clin Invest 85, 1328-1332 (1990)
171. Dahl LK, Heine M and Thompson K: Genetic influence of renal homografts on blood pressure of rats from different strains. Proc Soc Exp Biol Med 140, 852-856 (1972)
172. Dahl LK and Heine M: Primary role of renal homografts in setting chronic blood pressure levels in rats. Circ Res 36, 692-696 (1975)
173. Pravenec M, Kren V, Kunes J, Scicli AG, Carretero OA, Simonet L and Kurtz TW: Cosegregation of blood pressure with a kallikrein gene family polymorphism. Hypertension 17, 242-246 (1991)
174. Zinner SH, Levy PS and Kass EH: Familial aggregation of blood pressure in childhood. N Engl J Med 284, 401 (1971)
175. Zinner SH, Margolius HS, Rosner B and Kass EH: Stability of blood pressure rank and urinary kallikrein concentration in childhood: an eight-year follow-up. Circulation 58, 908-915 (1978)
176. Hunt SC, Slattery MA, Meikle AW and Williams RR: Environmental determinants of urinary kallikrein excretion. Am J Hypertens 6, 226-233 (1993)
177. Smith SR, Klotman, PE and Sventkey LP: Potassium chloride lowers blood pressure and causes natriuresis in older patients with hypertension. Am J Nephrol 2, 1302-1309 (1992)
178. Staessen JA, Birkhaeger W, Bulpitt CJ, Fagard R, Fletcher AE, Lijnen P, Thijs L and Amery A: The relationship between blood pressure and sodium and potassium excretion during the day and at night. J Hypertens 11, 443-447 (1993)
179. Damas J and Adams A: The kallikrein-kininogen-kinin system in the Brown Norway rat. Biomedicine 31, 249 (1979)
180. Damas J and Adams A: Congenital deficiency in plasma kallikrein and kininogens in the Brown Norway rat. Experientia 36, 586-587 (1980)
181. Damas J and Adams A: Sur une déficience en prékallikreine plasmatique chez une souche de rats Brown Norway. Arch Int Physiol Biochim 88, 511-514 (1980) (Abstr in English)
182. Oh-ishi S, Satoh K, Hayashi I, Yamazaki K and Nakano T: Differences in prekallikrein and high molecular weight kininogen levels in two strains of Brown Norway rat (Kitasato strain and Katholiek strain). Thromb Res 28, 143-147 (1982)
183. Oh-ishi S, Hayashi I, Satoh K and Nakano T: Prolonged activated thromboplastin time and deficiency of high molecular weight kininogen in Brown Norway rat mutant (Katholiek strain). Thromb Res 33, 371-377 (1984)
184. Oh-ishi S, Hayashi I, Hayashi M, Yamaki K, Yamasu A, Nakano T, Utsunomiya I and Nagashima Y: Evidence for a role of the plasma kallikrein-kinin system in acute inflammation: reduced exudation during carrageenin- and kaolin-pleurisies in kininogen-deficient rats. Agents Actions 18, 450-454 (1986)
185. Majima M, Katori M, Hanazuka M, Mizogami S, Nakano T, Nakao Y, Mikami R, Uryu H, Okamura R, Mohsin SSJ, and Oh-ishi S: Suppression of rat deoxycorticosterone-salt hypertension by kallikrein-kinin system. Hypertension 17, 806-813 (1991)
186. Yamasu A, Oh-isai S, Hayashi I, Hayashi M, Yamaki K, Nakano T and Syunahara N: Differentiation of kinin fractions in ureter urine and bladder urine of normal and kininogen-deficient rats. J Pharmacobiodyn 12, 287-292 (1989)
187. Hayashi I, Hoshiko S, Manabe O and Oh-ishi S: A point mutation of alanine 163 to threonine is responsible for the defective secretion of high molecular wreight kininogen by the liver of Brown Norway Katholiek rats. J Biol Chem 268, 17219-17224 (1993)
188. Lattion A-L, Baussant T, Alhenc-Gelas F, Seidah NG, Corvol P and Soubrier F: the high-molecular-mass kininogen deficient rat expresses all kininogen mRNA species, but does not export the high-molecular-mass kininogen synthesized. FEBS Lett 239, 59-64 (1988)
189. Oh-ishi S, Hayashi I, Utsunomiya I, Hayashi M, Yamaki K, Yamasu A and Nakano T: Roles of kallikrein-kinin system in acute inflammation: Studies on high- and low-molecular weight kininogen-deficient rats (B/N-Katholiek strain). Agents Actions 21, 384-386 (1987)
190. Oh-ishi S: Biological regulation by the kalukrein-kinin system: A study with a kininogen-deficient rat strain. Folia Pharmacol Jpn 101, 209-218 (1993) (Abstr in English)
191. Lacombe MJ Varet B and Levey J-P: A hitherto undescribed plasma factor acting at the contact phase of blood coagulation (Flaujeac Factor): Case report and coagulation studies. Blood 46, 761-768 (1975)
192. Wuepper KD, Miller RD and Lacome M-J: Flaujeac trait: Deficiency of human plasma kininogen. J Clin Invest 56, 1663-1672 (1975)
193. Colman RW, Bagdasarian A, Talamo RC, Scott CF, Seavey M, Guimaraes JA, Pierce JV and Kaplan AP: Williams trait: Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways. J Clin Invest 56, 1650-1662 (1975)
194. Donaldson VH, Glueck HI, Millar MA, Movat HZ and Habal F: kininogen deficiency in Fitzgerald trait: Role of high molecular weight kininogen in clotting and fibrinolysis. J Lab Clin Med 87, 327-337 (1976)
195. Hayashi H, Koya H, Kitajima K and Kitamura I: Coagulation factor deficiency apparently related to the Fitzgerald trait: The first case in Japan. Acta Med Okayama 32, 81-83 (1978)
196. Oh-ishi S, Ueno A, Uchida Y, Katori M, Hayashi H, Koya H, Kitajima K and Kimura I: Abnormalities in the contact activation through factor XII in Fujiwara trait: A deficiency in both high and low molecular weight kininogens with low level of prekallikrein. Tohoku J Exp Med 133, 67-80 (1981)
197. Nakamura K, Iijima K, Fukuda C, Kadowaki H, Ikorna H, Oh-ishi S, Uchida Y and Katori M: Tachibana trait: Human high molecular weight kininogen deficiency with diminished levels of prekallikrein and low molecular weight kininogen. Acta Hematol Jpn 48, 1473-1479 (1983)
198. Majima M, Mizogami S, Kuribayashi Y, Katori M and Oh-ishi S: Hypertension induced by a nonpressor dose of angiotensin II in kininogen-deficient rats. Hypertension 24, 111-119 (1994)
199. Majima M, Yoshida O, Mihara H, Muto T, Mizogami S, Kuribayashi Y, Katori M and Oh-ishi S: High sensitivity to salt in kininogen-deficient Brown Norway Katholiek rats. Hypertension 22, 705-714 (1993)
200. Majima M, Adachi K, Kuribayashi Y, Mizogami S and Katori M: Increase in vascular sensitivity to angiotensin II and norepinephrine after four-days infusion of 0.3 M sodium chloride in conscious kininogen-deficient Brown Norway Katholiek rats. Jpn J Pharmacol 69, 149-158 (1995)
201. Gelpi RJ, Hittinger L, Fujii AM, Crocker VM, Mirsky I and Vatner SF: Sympathetic augmentation of cardiac function early in developing hypertension in conscious dogs. Am J Physiol 255, H1525-H1534 (1988)
202. Shannon RP, Gelpi RJ, Hittinger L, Vatner DE, Homey CJ, Graham RM and Vatner SF: The inotropic response to norepinephrine is augumented early and maintained late in conscious dogs with perinephritic hypertension. Circ Res 68, 543-554 (1991)
203. Uemura N, Vatner DE, Shen Y-T, Wang J and Vatner SF: Increased α1-adrenergic vascular sensitivity during development of hypertension in conscious dogs. Am J Physiol 264, H1259-H1268 (1993)
204. Falloon BJ, Bund SJ, Tulip JR and Heagerty AM: In vitro perfusion studies of resistance artery function in genetic hypertension. Hypertension 22, 486-495 (1993)
205. Widgren BR, Herlitz H, Aurell M, Berglund G, Wikstrand J and Andersson OK: Increased systemic and renal vascular sensitivity to angiotensin II in normotensive men with positive family histories of hypertension. Am J Hypertens 5, 167-174 (1992)
206. Weidmann P: Pathogenetic and therapeutic relevance of cardiovascular pressor reactivity to norepinephrine in human hypertension. Clin Exp Hypertens 11, Supp 1, 257-273 (1989)
207. de Champlain J, Petrovich M, Gonzalez M, Lebeau R and Nadeau R: Abnormal cardiovascular reactivity in borderline and mild essential hypertension. Hypertension 17, Supp III, III-22-III-28 (1991)
208. Sasaki S, Takeda K, Okajima H, Takahashi H, Yoshimura M, Nakagawa M and Ijichi H: Pressor responses to intracisternal injection of hypertonic NaCl in rats. J Cardiovasc Pharmacol 6, 349-364 (1984)
209. Eagan BM: Neurogenic mechanisms of initiating essential hypertension. Am J Hypertens 2, 357S-362S (1989)
210. Berry CA and Rector FC Jr: Renal transport of glucose, amino acids, sodium, chloride and water. In The Kidney, Edited by Brenner BM and Rector FC Jr, 4th ed, Vol 1, pp 250-251, WB Saunders Co, Philadelphia, London, Toronto, Montreal, Sydney and Tokyo (1991)
211. Majima M, Ikeda Y, Kuribayashi Y, Mizogami S, Katori M and Aoyagi T: Ebelactone B, an inhibitor of urinary carboxypeptidase Y-like kininase, prevents the development of deoxycorticosterione acetate-salt hypertension in rats. Eur J Pharmacol 284, 1-11 (1995)
212. Majima M, Kuribayashi Y and Katori M: A novel type of antihypertensive drugs, poststatin and ebelactone B, acting through urinary kininase inhibition. Cand J Pharmacol Physiol 72, Supp I, 129 (1994)
213. Erdos EG and Skidgel RA: Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormone. FASEB J 3, 145-151 (1989)
214. Chiu PJS, Tetzloff G, Romano MT, Foster CJ and Sybertz EJ: Influence of C-ANP receptor and neutral endopeptidase on pharmacokinetics of ANF in rats. Am J Physiol 260, R208-R216 (1991)
215. Stephenson SL and Kenny AJ: The hydrolysis of α-human atrial natriuretic peptide by pig kidney microvillar membrane is initiated by endopeptidase-24.11. Biochem J 243, 183-187 (1987)
216. Shima M, Seino Y, Torikai S and Imai M: Intrarenal localization of degradation of atrial natriuretic peptides in isolated glomeruli and cortical nephron segments. Life Sci 43, 357-363 (1988)
217. Ura N, Carretero SA and Erdos EG: Role of renal endopeptidase 24.11 in kinin metabolism in vitro and in vivo. Kidney Int 32, 507-513 (1987)
218. Jardine AG, Counell JMC, Northridge D, Dilly SG, Cussans NJ, Davidson G, Doyle J, Leckie BL and Lever AF: The atriopeptidase inhibitor UK 69,578 increases atrial natriuretic factor and caused natriuresis in normal humans. Am J Hypertens 3, 661-667 (1990)
219. Gros C, Souque A, Schwartz J-C, Duchier J, Cournot A, Baumer P and Lecomte J-M: Protection of atrial natriuretic factor against degradation: Diuretic and natriuretic responses after in vivo inhibition of enkephalinase (EC 3.4.24.11) by acetophan. Proc Natl Acad Sci USA 86, 7580-7584 (1989)
220. Lecomte J-M, Baumer P, Lim C, Duchier J, Cournot A, Dussaule J-C, Araillou R, Gros C, Chaignon B, Souque A and Schwartz J-C: Stereoselective protection of exogenous and endogenous atrial natriuretic factor by enkephalinase inhibitors in mice and humans. Eur J Pharmacol 179, 65-73 (1990)
221. Shepperson NB, Barclay PL, Bennett JA and Samuels MR: Inhibition of neutral endopeptidase (EC 3.4.24.11) leads to an atrial natriuretic factor-mediated natriuretic, diuretic and antihypertensive response in rodents. Clin Sci 80, 265-269 (1991)
222. Tikkanen I, Helin K, Tikkanen T, Sybertz EJ, Vemulapalli S, Saiola H, Naveri H and Fyhrquist F: Elevation of plasma atrial natriuretic peptide in rats with chronic heart failure by SCH 39370, a neutral metalloendopeptidase inhibitor. J Pharmacol Exp Ther 254, 641-645 (1990)
223. Northridge DB, Jardine AG, Findlay IN, Archibald M, Dilly SG and Dargie HJ: Inhibition of the metabolism of atrial natriuretic factor caused diuresis and natriuresis in chronic heart failure. Am J Hypertens 3, 682-687 (1990)
224. Dussaule J-C, Grange J-D, Wolf J-P, Lecomte J-M, Gros C, Schwartz J-C, Bodin F and Ardaillou R: Effect of sinorphan, an enkephalinase inhibitor, on plasma atrial natriuretic factor and sodium urinary excretion in cirrhotic patients with ascites. J Clin Endocrinol Metab 72, 653-659 (1991)
225. Ishida H, Scicli AG and Carretero OA: Contributions of various rat plasma peptidases to kinin hydrolysis. J Pharmacol Exp Ther 251, 817-820 (1989)
226. Sybertz EJ, Chiu PJS, Vemulapalli S, Watkins R and Haslanger MF: Atrial natriuretic factor-potentiating and antihypertensive activity of SCH 34826 - An orally active neutral metallopeptidase inhibitor. Hypertension 15, 152-161 (1990)
227. Seymour AA, Norman JA, Asaad MM, Fennell SA, Swerdel JN, Little DK and Dorso CR: Renal and depressor effects of SQ 29,072, a neutral endopeptidase inhibitor, in conscious hypertensive rats. J Cardiovasc Pharmacol 16, 163-172 (1990)
228. Sybertz EJ: SCH 34826: an overview of its profile as a neutral endopeptidase inhibitor and ANF potentiator. Clin Nephrol 36, 187-191 (1991)
229. Sybertz EJ, Chiu PJS, Watkins RW and Vemulapalli S: Neutral metalloendopeptidase inhibitors as ANF potentiators: sites and mechanisms of action. Can J Physiol Pharmacol 69, 1628-1635 (1991)
230. Hirata Y, Matsuoka H, Hayakawa H, Sugimoto T, Suzuki E, Sugimoto T, Kanagawa K and Matsuo H: Role of endogenous atrial natriuretic peptide in regulating sodium excretion in spontaneously hypertensive rats. Hypertension 17, 1025-1032 (1991)
231. Cavero PG, Margulies KB, Winaver J, Seymour AA, Delaney NG and Burnett JC Jr: Cardiorenal actions of neutral endopeptidase inhibition in experimental congestive heart failure. Circulation 82, 196-201 (1990)
232. Suzuki E, Hirata Y, Matsuoka H, Sugimoto T, Hayakawa H, Sugimoto T, Kanagawa K, Minamino N and Matsuo H: Characterization of atrial natriuretic peptide in urine from rats treated with a neutral endopeptidase inhibitor. Biochem Biophys Res Commum 182, 1270-1276 (1992)
233. Kenny AJ and Stephenson SL: Role of endopeptidase-24.11 in the inactivation of atrial natriuretic peptide. FEBS Lett 232, 1-8 (1980)
234. Roques BP, Fournie-Zaluski M-C, Soroca E, Lecomte JM, Malfroy B, Liorens C and Schwarz J-C: The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice. Nature 288, 286-288 (1980)
235. Ronco P, Pollard H, Galceran M, Delauche M, Schwartz JC and Verroust P: Distribution of enkephalinase (membrane metalloendo-peptidase EC 3.4.24.11) in rat organs: Detection using a monoclonal antibody. Lab Invest 58, 210-217 (1988)
236. Smits GJ, McGraw SE and Trapani AJ: Interaction of ANP and bradykinin during endopeptidase 24.11 inhibition: renal effects. Am J Physiol 258, F1417-F1424 (1990)
237. Sybertz EJ, Chiu PJS, Vemulapalli S, Pitts B, Foster CJ, Watkins RW, Barnett A and Haslanger MF: SCH 39370, a neutralmetalloendopeptidase inhibitor potentiates biological responses to atrial natriuretic factor and lowers blood pressure in desoxycorticosterone acetate-sodium hypertensive rats. J Pharmacol Exp Ther 250, 624-631 (1989)
238. Ura N, Shimamoto K, Kuroda S, Nomura N, Iwata M, Aoyama T and Iimura O: The role of kinins and atrial naturiuretic peptide on the renal effects of neutral endopeptidase inhibitor in rats. Clin Exp Hypertens 16, 799-808 (1994)
239. Ogata H, Ura N, Shimamoto K, Sakakibara T, Ando T, Nishimiya T, Nakagawa M, Fukuyama S, Masuda A, Yamaguchi Y, Ise T, Saito S, Shiiki M, Uno K and Iimura O: A sensitive method for differential determinatioan of kininase I, II and neutral endopeptidase (NEP) in human urine. In Adv Exp Med Biol, Vo1 247B, Kinins V, Part B, Edited by Abe K, Moriya H and Fujii S, pp 343-348, Plenum Press, New York (1989)
240. O'Connell JE, Jardine AG, Davidson G and Connell MC: Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension. J Hypertens 10, 271-277 (1992)
241. Sagnella GA, Singer DRJ, Markandu ND, Buckley MG and MacGregor GA: Is atrial natriuretic peptide-guanosine 3′,5′ cyclic monophosphate coupling a determinant of urinary sodium excretion in essential hypertension? J Hypertens 10, 349-354 (1992)
242. Ogihara T, Rakugi H, Masuo K, Yu H, Nagano M and Mikami H: Antihypertensive effects of the neutral endopeptidase inhibitor SCH 42495 in esential hypertension. Am J Hypertens 7, 943-947 (1994)
243. Bevan EG, Connell JMC, Doyle J, Carmichael HA, Davies DL, Lorimer AR and McInnes GT: Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens 10, 607-613 (1992)
244. Burnier M, Porchet M, Ganslmayer M, Nussberger J, Kosoglou T, Waeber B and Brunner H: Naturiuretic effects of SCH 34826, an orally active neutral endopeptidase (NEP) inhibitor: Results of a randomized four way crossover study in salt loaded volunteers. J Hypertens 8, Supp 3, s99 (1990)
245. Kosoglou T, Herron JM, Chen R, Given B, Sybertz EJ and Affrime MB: Antihypertensive effect of the atriopeptidase inhibitor SCH 34826 in essential hypertension. Circulation 82, Supp II, 2201 (1990)
246. Amico JA, Seif SM and Robinson AG: Oxytocin in human plasma: Correlation with neurophysin and stimulation with estrogen. J Clin Endocrinol Metab 52, 988-993 (1981)
247. Leake RD, Weitzman RE, Glatz TH and Fisher DA: Plasma oxytocin concentrations in men, nonpregnant women, and pregnant women before and during spontaneous labor. J Clin Endocrinol Metab 53, 730-733 (1981)